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 Glycoproteins are an integral type of treatment to modern medicine.  
Glycoproteins are proteins which are adorned with sugar chains known as glycans.  
Asparagine-linked glycans, also called N-glycans, are of particular importance.  They are 
involved in many cellular processes such as cell signaling, protein folding, and secretion 
of products.  While the beginning of the N-glycosylation pathway is mostly the same 
across eukaryotic organisms, the glycosylation pathways diverge in later steps, causing 
foreign N-glycans to be immunogenic to humans.  This limits the possible production 
hosts for such glycoproteins used in medicine to hosts which produce similar enough 
glycans to humans that they will not cause immune rejection.  In the industry today, most 
glycoproteins are produced by mammalian cell lines such as Chinese hamster ovary 
(CHO) cells.  These cell lines produce glycoproteins containing glycans very similar to 
humans, however, they are very expensive to culture.  Filamentous fungi such as 
Aspergillus nidulans produce and secrete glycoproteins at a much higher rate and grow in 
cheaper media, however, the glycans they produce are immunogenic to humans. 
 In order to obtain more cost-effective glycoprotein production, A. nidulans can be 
engineered to produce human-like glycans.  To achieve this end, this study uses an A. 
nidulans strain which has been engineered to produce glycans with fewer mannose 
residues and inserts an och1-GnTI fusion protein.  The och1 section of this fusion protein 
is meant to direct the protein to the Golgi apparatus membrane, where it can then add N-
acetylglucosamine (GlcNAc) to the glycans.  This is a necessary step in the process to 
achieve humanized glycosylation in A. nidulans.  Expression and activity of this fusion 
protein is analyzed using qRTPCR, Western, and lectin blotting.  The qRTPCR and 
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Western blot both show expression of GnTI, and the lectin blot indicates additional 
GlcNAcylation in the transformant strains compared to the parent strain.  Both 
transformant strains produced in this study appear to express GnTI and actively 
GlcNAcylate glycoproteins. 
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Chapter 1. Introduction 
 In protein therapeutics, N-glycans play an important role in the efficacy of 
treatments.  Most eukaryotes attach sugars to proteins at NXS/T amino acid motifs, 
where X is any amino acid except proline, in a process known as N-glycosylation [1].  
These glycans have widespread effects in a cell, being involved in processes such as 
protein folding, cell signaling, and product secretion [2].  The glycosylation pathways in 
most eukaryotes are identical in the earlier steps, however, species of different kingdoms 
tend to utilize different patterns of monomers in the construction of glycans in the 
process’ later phases [3].  The result is that the glycan structures can vary greatly between 
organisms.  As the result of this variation, the human immune system detects and quickly 
disposes of foreign glycoproteins [4, 5].  Because of this, glycoprotein therapeutics are 
usually produced in closely related mammalian cells, most commonly Chinese hamster 
ovary (CHO) cells [6]. 
 While CHO cells are useful for their ability to produce similar glycans to those 
found in humans, they are outclassed in terms of protein production rate by filamentous 
fungi .  After years of improving culturing methods for productivity, CHO cells have 
reportedly reach a product yield of 4.7 g/L, while yields exceeding 20 g/L have been 
reached using the filamentous fungus Aspergillus niger [7, 8].  Fungi naturally secrete 
proteins as a method of breaking down extracellular carbon sources for consumption.  
Because of this natural necessity, fungi have evolved a more well-tuned secretion system, 
giving them a higher protein secretion rate.  Additionally, production of medically 
relevant proteins in fungi is advantageous because fungal growth media is cheaper and 
characterized as opposed to mammalian growth media, which is expensive and 
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proprietary, so its components are unknown.  Fungal cultures are also not susceptible to 
viral contamination, which can be a major production cost in mammalian production 
systems [9].  Between all of these advantages, fungal expression systems represent a 
promising alternative to mammalian systems for producing therapeutic proteins, as they 
would allow for quicker and more cost effective production of these proteins. 
 
Figure 1. Glycosylation pathways.  A) Natural N-glycosylation pathways in mammals and filamentous 










The largest obstacle in utilizing fungi, however, is that their glycosylation 
pathway is very different from that of mammals.  While mammalian glycosylation 
pathways often result in what are known as complex glycans, fungal pathways result in 
high-mannose glycans, as seen in Figure 1 [10].  The complex glycans of mammals are 
characterized by their use of several different sugar monomers, notably N-
acetylglucosamine (GlcNAc), galactose, and N-acetylneuraminic acid, commonly 
referred to as sialic acid.  In contrast, the high-mannose glycans of filamentous fungi are 
characterized by their large, branching structures consisting almost entirely of mannoses 
[11].  These high-mannose glycans are immunogenic in humans.  Therefore, in order to 
utilize fungi to their full potential as production hosts, their glycosylation pathways must 
be engineered to result in glycans resembling those produced by a human pathway. 
In order for fungi to be used to produce nonimmunogenic glycoproteins, they 
should produce a glycan resembling that shown at the end of the mammalian 
glycosylation pathway in Figure 1.  While the human glycome consists of several glycan 
structures of a wide variety, this particular glycan serves as a good model due to its sialic 
acid caps and requiring less transformation steps to be achieved [12].  Sialic acid is of 
particular importance because it plays a key role in extending the circulatory lifetime of 
the glycoprotein [13].  Glycoproteins with glycans containing terminal galactose or 
GlcNAc residues are cleared from the circulatory system by the asialoglycoprotein-
receptor (ASGP-R), expressed by liver parenchymal cells.  Glycoproteins with terminal 
sialic acid residues, however, are not cleared by ASGP-R, increasing their circulatory 
lifetime [14].  As a consequence of increased circulatory lifetime, glycoprotein 
therapeutics containing terminal sialic acids on their glycans also have increased efficacy 
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[15].  To achieve terminally sialylated glycans from a fungal expression host, the 
mannosylation which is natural to fungi must be reduced, and mammalian glycosylation 
pathways must then be introduced into the fungi. 
 In this study, an engineered strain of Aspergillus nidulans has been used, known 
as A. nidulans 2161 [16].  This strain has had the nkuA, alg3, alg9, and alg12 genes 
deleted, as well as an α-mannosidase, glucosidase II, Mns1B, and β-glucosidase 
overexpressed.  Alg3, 9, and 12 function as mannosyltransferases in the endoplasmic 
reticulum (ER).  By targeting the enzymes acting early on in the glycosylation pathway, 
the resulting glycan can more easily be reduced to Man3GlcNAc2, a template structure 
which is common to mammals and fungi, which will then be built off of by the insertion 
of mammalian glycosylation genes.  The added α-mannosidase also serves to reduce the 
extent of mannosylation in order to achieve this starting template by cleaving the α-1,2 
mannoses attached to the α-1,3 mannose branch [17].  The glucosidase II is an enzyme 
that cleaves glucose caps which, when overexpressed, was shown to allow the fungi to 
produce a higher proportion glycans consisting of five or less mannoses [16].  The 
overexpressed β-glucosidase is secreted and serves as a model protein to study the effects 
of these genetic modifications on glycosylation. 
 The nkuA gene, which has been deleted in this strain, is a gene involved in the 
non-homologous end joining (NHEJ) DNA repair pathway [18].  This is one of two DNA 
repair pathways utilized by fungi, the other being homologous recombination.  
Homologous recombination is often used as a method of targeted gene insertion or 
deletion in fungi [19].  It utilizes large lengths of homologous regions of DNA upstream 
and downstream of both the target genomic site and the insert, and lines up these 
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homologous regions to “repair” the damaged genomic DNA using the insert DNA as a 
template, resulting in the insertion or deletion of a gene of interest.  NHEJ naturally 
opposes this process, as it is an alternative DNA repair mechanism which would not 
result in the usage of transformed DNA as a template, therefore not resulting in any 
genomic sequence changes.  By deleting nkuA, NHEJ becomes drastically less 
functional, requiring that homologous recombination be used for DNA repair, thus 
increasing the success rate of targeted gene insertion or deletion. 
 This study aims to build off the Man3-producing strains engineered by Anyaogu 
et. al [16].  To accomplish this, the gene encoding a human GlcNAc transferase, GnTI, 
has been introduced into A. nidulans 2161.  GnTI is a membrane protein which must be 
localized to the Golgi apparatus in order to properly modify glycans, as this is where 
glycoproteins are sent for late-stage glycan modification and subsequent secretion [20].  
Proteins that are designated to particular subcellular locations require signal peptides to 
be directed to their target destination correctly.  These signal peptides can vary between 
species.  Additionally, the mammalian transmembrane domain may be less functional in 
fungi due to differing membrane compositions between the species.  Therefore, it is 
important that the signal peptide and transmembrane domains of the mammalian GnTI be 
replaced with an alternative that will function in A. nidulans. Similar studies have used a 
combinatorial library in order to target GnTI to the fungal Golgi apparatus in the past; 
however, in this study, the signal peptide and transmembrane domain of the putative 
fungal mannosylation gene, och1, were used to replace the human signal peptide and 




Figure 2. Gene construct.  A) GnTI gene, consisting of a signal peptide (SP), transmembrane domain 
(TM), and functional region (FR).  Primer annealing sites and overhangs are represented by arrows.  B) 
Och1 gene, including the upstream (US) and downstream (DS) regions.  Grey primer overhangs represent 
restriction sites, with NotI on the US side and XbaI on the DS side.  C) Initial PCR products shown 
overlapping at sites where annealing occurs during fusion PCR.  D) Final gene construct.  Segment lengths 
are not to scale. 
In order for f-GnTI to be targetedly inserted into the fungal genome, a three-part 
gene construct was built.  This construct consists of the f-GnTI gene itself and an 
upstream and downstream homologous region, which are homologous to sections in the 
fungal genome and flank the GnTI gene on each end, targeting the gene to the genomic 
location at which the homologous regions align.  The och1 putative gene encodes a 
mannosyltransferase which acts early on in the glycosylation pathway in the Golgi [11].  
Furthermore, och1 adds a mannose residue as an additional branch on the glycan, 
providing a mannose substrate for subsequent Golgi-localized mannosyltransferases to 
act on without needing to compete for substrate with GnTI, which has specificity for the 
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α-1,3 mannose branch [3].  Ultimately, och1 activity would result in undesirable 
mannosylation of the glycans.  By flanking the GnTI insert with the upstream and 
downstream sequences of och1, homologous recombination can be used to 
simultaneously delete the unwanted och1 and replace it with GnTI.  Additionally, by 
utilizing only the functional region of the GnTI gene without its native signal peptide and 
transmembrane domain, these regions can be replaced with the fungal equivalents that are 
native to och1 by leaving the och1 signal peptide and transmembrane domains as the 3’ 
end of the upstream homologous region used for targeting GnTI to the och1 gene’s 
location in the genome.  This method also allows for any native promoters and enhancers 




Chapter 2. Background 
2.1. 5-Fluoroorotic Acid Counterselection 
In this study, 5-fluoroorotic acid (5-FOA) counterselection was utilized to reuse 
the pyrG selection marker for transforming the fungi.  PyrG is an auxotrophic selection 
marker which is involved in the synthesis of uracil from orotidine 5-phosphate [22].  
Strains which are pyrG deficient must be supplemented with uridine and uracil in order to 
grow.  To utilize this, the pEXpyr plasmid used in this study contains a pyrG selection 
marker, which restores the fungi’s ability to synthesize uracil, allowing them to grow on 
selective plates which do not contain uridine or uracil.  The pyrG gene is flanked by 
mate1 sequences, which are direct repeats [23].  Fungi will randomly undergo a 
recombination event in which the sequence between these mate1 sequences will be 
excised from the genome.  5-FOA is a fluorinated molecular mimic of orotidine 5-
phosphate, which, when converted to 5-fluorouracil by the activity of pyrG, becomes 
toxic to the cell and kills it.  This allows for the selection of those colonies which have 
undergone the random recombination event and thus have removed the pyrG selection 
marker, allowing it to be reused in subsequent transformations [24].  The gene that was 
transformed into the fungi is not lost with the pyrG selection marker because it is not in 





Figure 3. 5-FOA counterselection process.  Fungal genotypes are shown in green ovals.  Gene of interest 
is represented by “GOI.” 
2.2. qRTPCR 
The expression of GnTI at the mRNA level was measured using quantitative 
reverse transcriptase PCR (qRTPCR).  The basis of this method lies in the use of an 
intercalating dye which increases the fluorescence of the solution as the amount of DNA 
increases.  By using a thermocycler that can measure fluorescence, comparisons of DNA 
concentration can be made in real time as the PCR process is carried out.  The template 
DNA for each sample is the cDNA made by reverse transcribing the total RNA of a 
culture.  Because PCR doubles the amount of DNA with each cycle, the amount of DNA 
present in the sample at any given time, and thus the fluorescence of the sample, directly 
correlates with the initial amount of cDNA template for the target region.  A threshold 
fluorescence value is computationally decided, which is the lowest fluorescence value 
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that is statistically significantly different from the baseline fluorescence reading.  The 
cycle at which each sample reaches this threshold value, CT, is recorded.  Due to the 
exponential nature of PCR, it can be concluded that the ratio of starting amount of cDNA 
for a target gene in one sample compared to another is equal to 𝑅𝐸 = 2
𝐶𝐸𝑇2−𝐶𝐸𝑇1, where 
RE is the ratio of initial cDNA of the experimental gene in sample 1 compared to sample 
2, CET1 is the cycle at which sample 1’s fluorescence reached the threshold value, and 
CET2 is the cycle at which sample 2’s fluorescence reached the threshold value.  In order 
to control for difference between the initial amount of cDNA loaded into each sample, a 
housekeeping gene is usually used.  A housekeeping gene can be any gene which is 
expressed at an equal amount in each experimental and control sample.  Actin and 
histone genes are a few examples of commonly used housekeeping genes.  To correct for 
differential sample loading, a ratio of expression of the housekeeping gene must be found 
using 𝑅𝐻 = 2
𝐶𝐻𝑇2−𝐶𝐻𝑇1, where RH is the ratio of initial cDNA for the housekeeping gene 
between samples 1 and 2, and CHT1 and CHT2 are the cycles at which samples 1 and 2 
reached the fluorescence threshold, respectively.  The ratio of expression of the 
experimental gene can then be found by using 𝑅 = 𝑅𝐸/𝑅𝐻. 
2.3. Western and Lectin Blotting 
 Western and Lectin blots are methods for visualizing the presence or absence of 
target proteins.  They function by loading a solution containing several types of proteins, 
often cell lysate or media, into an SDS-PAGE gel and running an electrical current 
through the gel to separate the proteins by size.  These proteins are then transferred to a 
membrane which binds proteins.  In Western blotting, an antibody for a protein of interest 
is used, which will specifically bind to the protein of interest if it is present.  This 
13 
 
antibody is referred to as the primary antibody.  A secondary antibody is then used which 
has specificity for the constant region of the primary antibody and is attached to a 
conjugate which enables visualization of the proteins.  Lectin blots, rather than utilizing 
antibodies with protein specificity, rely on lectins.  Lectins are a class of protein which 
have specific binding for monosaccharides which can commonly be found on glycans.  
Lectins can be conjugated to a visualization molecule directly or to biotin, which allows 
any visible molecule conjugated to streptavidin to be used to visualize the lectin, and by 




Chapter 3. Materials and Methods 
3.1. Strains and Media 
 The parent strain used in this study was Aspergillus nidulans 2161 [16].  From 
this strain, A. nidulans 3162 and 3168 were created by transforming A. nidulans 2161 
with the human MGAT1 gene, which was randomly inserted into the genome, yielding 
these two transformant strains.  All strains were grown at 28 °C for agar or liquid media, 
and strains grown in liquid media were grown in a shaking incubator at 250 RPM unless 





















Malt extract 20 g/L 
Peptone 2 g/L 
Glucose 20 g/L 
Vitamin mix 1X 
Hutner's Solution 1X 
YGV 
Yeast extract 5 g/L 
Glucose 20 g/L 
Vitamin mix 1X 
Hutner's Solution 1X 
Minimal Media + Sorbitol 
D-Sorbitol 1.2 M 
Glucose 20 g/L 
Vitamin mix 1X 
Hutner's Solution 1X 
Ammonium Chloride 5 g/L 
Minimal Media 
Glucose 10 g/L 
Magnesium Sulfate   
Nitrate Salts 1X 
Vitain mix 1X 
Hutner's Solution 1X 
Vitamin mix (1000X) 
Biotin 100 mg/L 
Pyridoxin 100 mg/L 
Thiamine 100 mg/L 
Riboflavin 100 mg/L 
P-aminobenzoic acid 100 mg/L 









Hutner's Solution (1000X) 
Component Concentration 
 ZnSO4 • 7H2O  22 g/L 
 H3BO3  11 g/L 
 MnCl2 • 4H2O  5 g/L 
 FeSO4 • 7H2O  5 g/L 
 CoCl2 • 6H2O  1.6 g/L 
 CuSO4 • 5H2O  1.6 g/L 
 (NH4)6Mo7O24 • 4H2O  1.1 g/L 
 EDTA  50 g/L 
Table 1. Media compositions 
Media requiring uracil and uridine (UU) supplements have 1.12 g/L and 1.22 g/L 
of uracil and uridine, respectively, in addition to the media’s normal components as listed 
above. Agar-containing media was made using the listed recipes above with the addition 
of 2% w/v agarose. MAGV+UU+5-FOA agar was made using 1.3 mg/mL 5-FOA [26]. 
3.2. Strain Banking 
 Upon receiving A. nidulans 2161 or upon creating a new strain, strains were 
banked by first growing them in liquid MAGV media, supplemented with uridine and 
uracil if necessary.  After 2-3 days of growth, 300 μL of media were plated onto each of 3 
MAGV agar plates, supplemented with uridine and uracil if necessary, and allowed to 
grow for 3 days.  8 mL of PBS was then pipetted onto each plate, and the spores scraped 
off using a scraper.  The PBS and spore solutions were combined and then vortexed at 
high speed for 60 seconds.  The solution was then pushed through a sterile 60-mL syringe 
with sterile glass wool in the bottom, removing the mycelia from the spore solution.  
Spores were then counted and diluted using PBS to 1x107 spores/mL in a solution with 
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20% glycerol.  The spore solutions were then split into 1-mL aliquots and frozen at -80 
°C. 
3.3. 5-FOA Counterselection 
 After banking A. nidulans 2161, it was first grown on MAGV+UU+5-FOA plates.  
After growing for 7 days at 28 °C, colonies were then picked using a sterile pipette tip 
and grown in MAGV+UU liquid media for banking. 
3.4. Gene and Plasmid Construction 
 The plasmid backbone used in this study was pEXpyr.  The och1 upstream and 
downstream regions were first PCRed from A. nidulan 2161 genomic DNA using primers 
och1_US_F and och1_US_R for the upstream region and och1_DS_F and och1_DS_R 
for the downstream region. GnTI with a truncated signal peptide and transmembrane 
domain (GnTI-dTM) was PCRed from E. coli lysate containing the human gene for GnTI 
using primers GnTI_dTM_F and GnTI_R.  E. coli containing GnTI was ordered from 
DNASU.  PCR products were then gel extracted using QIAquick Gel Extraction Kit 
(Qiagen) according to the manufacturer’s protocol with modifications to increase yield.  
Modifications include running the initial sample through the column three times and 
allowing the PB buffer to evaporate for 5 minutes before adding nuclease free water to 
the column, which was used in place of elution buffer.  The nuclease free water was also 
allowed to sit on the column for 5 minutes before being centrifuged through.  1 μL of 
each of the och1 upstream region and GnTI-dTM were then used as template in a 
subsequent fusion PCR reaction.  The product was then gel extracted, and 1 μL of 
purified product was then used with 1 μL of the och1 downstream DNA in another PCR 
reaction.  All PCR reactions were conducted using Phusion HF polymerase (New 
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England Biolabs) according to manufacturer’s instructions.  The completed and purified 
construct and pEXpyr were then digested using NotI and XbaI restriction enzymes (New 
England Biolabs).  The insert and plasmid were then cleaned up using a QIAquick PCR 
Purification Kit (Qiagen), used according to the manufacturer’s protocol with the same 
modifications listed for the gel extraction protocol, and were ligated at room temperature 
for 15 minutes in a 5:1 insert to vector ratio using T4 DNA ligase (New England 
Biolabs), creating the plasmid pEXpyr-GnTIcas.  2 μL of the ligation reaction were then 
used in a transformation into NEB 5-alpha competent E. coli (New England Biolabs) 
according to the manufacturer’s protocol. 
Primers 













Table 2. Primer sequences.  Underlined regions represent overhangs. 
3.5. Transformation 
Flasks containing 150 mL of YGV+UU media were first inoculated with 1x107 
spores of counterselected A. nidulans 2161 and grown at 28°C and 200 RPM for 24 
hours.  Cultures were then slowly poured through a nylon mesh with regular shaking of 
the flask to separate the media from the mycelia.  The mycelia were then scraped into a 
50-mL conical tube using a sterile spatula.  The 50-mL conicals were then filled with 20-
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30 mL of lysing enzyme solution containing 6 g/L Lallzyme MMX (Lallemand).  The 
tube was then secured on its side and incubated at 30 °C while shaking at 100 RPM for 2 
hours.  After incubation, the solution was poured through 2 layers of sterile Miracloth in 
a funnel into a new 50-mL conical tube.  The protoplast solution was then centrifuged at 
4000 xg and 4°C for 10 minutes.  The supernatant was removed and the pellet was then 
resuspended in 50 mL STC 50.  STC 50 is made up of 218.6 g/L D-Sorbitol, 1.48 g/L 
CaCl2 • 2H2O, and 1/20 of the total volume of Tris HCl pH 7.5 (1 M).  The protoplasts 
were then centrifuged and resuspended in 50 mL of STC 50 a second time.  After the 
final wash, the protoplasts were centrifuged at 4000 xg and 4°C for 10 minutes, and then 
resuspended in 1 mL STC 50.  150 μL of this protoplast solution was taken and added to 
a 15-mL conical tube.  10 μg of pEXpyr plasmid with insert was then added to the 150-
μL protoplast solution, and the volume filled up to a total of 200 μL with STC 50.  This 
solution was then incubated at room temperature for 20 minutes.  After incubation, 2 mL 
of 60% PEG-8000 solution was added to the protoplasts, and the solution was incubated 
for another 15 minutes at room temperature.  STC 50 was then added to bring the total 
volume up to 12 mL, and the tube was inverted gently until the solution was thoroughly 
mixed.  2 mL of this solution was then plated onto each of 6 plates containing 
MM+Sorbitol+Agar and allowed to grow for 6 days.  Transformant colonies were then 
picked using a sterile pipette tip and each replated onto a new MM+Sorbitol+Agar plate 
and allowed to grow for 5 days. 
3.6. Transformant Screening 
 Transformants which showed growth after replating were picked using a sterile 
pipette tip and grown in 50 mL of MAGV media for 3 days.  Some of the media was 
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taken and plated onto MAGV plates for banking, and the rest was used for genomic DNA 
extraction using the Fungi/Yeast Genomic DNA Isolation Kit (Norgen Biotek) according 
to the manufacturer’s protocol.  The extracted genomic DNA was then used as template 
in two PCR reactions for each transformant using primers och1_US_F and och1_DS_R 
for the first reaction and och1_US800_F and och1_DS800_R for the second.  The PCR 
products were then run on an electrophoresis gel, and bands corresponding to 2100 bp 
from the first reaction and 2900 bp from the second reaction were gel extracted and 
sequenced.  Sequencing revealed two colonies which contained the GnTIcas insert, A. 
nidulans 3162 and 3168, which were then used for further analysis. 
3.7. qRTPCR 
 Strains were first inoculated into 50 mL of YGV media and grown for 24 hours.  
The contents of the 50-mL culture were then poured into a 2.8-L flask filled with 1 L of 
YGV.  The 1-L culture was then allowed to grow for 2 days.  The media was then poured 
through 2 layers of Miracloth in a funnel.  After the entire culture had been run through, 
remaining media was squeezed out of the mycelia clump.  Smaller clumps of mycelia 
were then broken off and freeze-dried using liquid nitrogen, and then ground using a 
mortar and pestle while being kept frozen using liquid nitrogen until the mycelia became 
a fine powder.  This lysate was then used in the RNeasy Plus Universal Mini Kit 
(Qiagen) and RNA was extracted using the manufacturer’s protocol. 
 Extracted RNA was then used in a reverse transcriptase PCR reaction using 
random primers.  The cDNA obtained from the RTPCR was then amplified using primers 
GnTI_mRNA_F and GnTI_mRNA_R in qPCR reactions using SYBR Select Master Mix 
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(Applied Biosystems).  Additional qPCR reactions of the cDNA templates using primers 
His2B_mRNA_F and His2B_mRNA_R were carried out in parallel as loading controls. 
3.8. Western Blotting 
 Crude protein extract was obtained by first inoculating 200 mL cultures with 
2x107 spores and allowing them to grow for 3 days.  Mycelia were then extracted and 
lysed by freeze drying and crushing with a mortar and pestle, as described in section 3.7.  
Lysate was then dissolved in RIPA buffer by continuous rotation for 1 hour at 4°C and 
centrifuged to remove cellular debris.  Protein concentration of prepared samples was 
then measured with a BCA assay. 
Protein from lysate for each sample was loaded in duplicate onto an SDS-PAGE 
gel, with 8 µg of protein in one well and 16 µg in a second.  The SDS-PAGE gel was run 
and proteins were then transferred onto a PVDF membrane at 100 V for 75 minutes.  
Western blot was performed using PBST as a wash buffer and Carbo-Free Blocking 
Solution (Vector Labs) as a blocking buffer.  Goat pAb to B3GNTI (Abcam) was used as 
the primary antibody to screen for GnTI expression.  Membrane was incubated overnight 
at 4°C with gentle shaking in primary antibody solution containing blocking buffer 
diluted using PBST to 1:5 blocking buffer to total solution and 0.15 µg/mL of primary 
antibody.  HRP horse anti-goat IgG antibody (Vector Labs) was used as the secondary 
antibody, which was bound by gently shaking the membrane at room temperature for 2 
hours in 1:5 blocking buffer diluted in PBST. 
3.9. Lectin Blotting 
 Protein from lysate for lectin blotting was prepared as described above.  Secreted 
protein was prepared by first growing inoculating 200 mL of minimal media with 2x107 
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spores of A. nidulans strains and allowing them to grow in a shaking incubator for 2 days.  
Mycelia were separated from the media by filtering the media through a miracloth filter 
in a funnel and squeezing out any additional media from the mycelia clump.  The protein 
concentrations of each sample were measured using a BCA assay, and 6 µg of protein 
were loaded for each sample into an SDS-PAGE gel.  After running the SDS-PAGE gel, 
proteins were transferred to a PVDF membrane at 100 V for 75 minutes.  Membrane 
washes were performed using PBST.  Biotinylated wheat germ agglutinin (WGA) was 
used to bind terminal GlcNAc residues [27].  The membrane blocked using Carbo-Free 
blocking solution (Vector Labs).  WGA binding was performed by incubating the 
membrane overnight with gentle shaking at 4°C in PBST with 5 µg/mL WGA.  
Horseradish peroxidase streptavidin ELISA grade (HRP-streptavidin) (Vector labs) was 
used for visualization, and was bound to WGA by incubating the membrane for 1 hour 
with gentle shaking at room temperature in 5 µg/mL HRP-streptavidin in PBST. 
3.10. Coomassie Blue Staining 
 The samples used in the lectin blot described above were loaded into an additional 
SDS-PAGE gel.  After running, the gel was incubated in Coomassie blue overnight with 
gentle shaking at 4°C for initial staining.  The gel was then washed in destaining buffer 
for 2 hours with gentle shaking at room temperature.  The destaining buffer was changed 
out for fresh destaining buffer and incubated for an additional 2 hours before the buffer 






Chapter 4. Results 
4.1. Transformant Screening 
 Transformations were initially attempted by growing A. nidulans 2161 in YGV 
for 12 hours, as was typical for transformations of parent A. nidulans strains using this 
protocol.  After this 12 hour period, however, the culture did not appear sufficiently 
cloudy when using A. nidulans 2161, as was normal when using parent strains, likely due 
to the heavy genetic modification of this strain.  Consequently, the initial growing step 
was increased from 12 to 24 hours.  Additionally, fungi were not surviving the 
transformation protocol when using a 3-hour incubation step in the lysing enzyme 
solution, which was normal when working with parent A. nidulans strains.  
Transformation of A. nidulans 2161 was successful after reducing this incubation step to 
2 hours. 
After transformation of A. nidulans 2161 with pEXpyr-GnTIcas, the genomic 
DNA of 6 resulting colonies was isolated and used as a template in PCR reactions using 
primers och1_US_F and och1_DS_R for one amplification and och1_US800_F and 
och1_DS800_R for a second.  Of these, bands corresponding to 2100 bp from the first 
reaction and 2900 bp from the second were gel extracted and sequenced.  Sequencing 
using och1_US_F and och1_DS_R revealed that A. nidulans 3162 and 3168 amplicons 
both aligned with GnTI, however, sequencing using och1_US800_F and och1_DS800_R 






Template DNA Primer GnTI och1 US och1 och1 DS 
A. nidulans 
3162 
och1_US_F x x     
och1_DS_R x     x 
och1_US800_F   x x   
och1_DS800_R     x x 
A. nidulans 
3168 
och1_US_F x x     
och1_DS_R x     x 
och1_US800_F   x x   
och1_DS800_R     x x 
Table 3. Transformant sequencing results summary.  Boxes filled with “x” represent results in which 
the sequence from genomic DNA aligned with the listed genes. 
4.2. qRTPCR 
 A. nidulans 2161, 3162, and 3168 mRNA was prepared, and cDNA was created 
from the mRNA templates using RTPCR.  The cDNA of each strain was then amplified 
using qPCR for GnTI and Histone 2B in separate PCR reactions, each run in triplicate, to 
verify the expression of GnTI at the mRNA level in A. nidulans 3162 and 3168. 
 
Figure 4. qRTPCR for GnTI.  Amount of DNA present in each sample is tracked over the course of the 
PCR protocol using fluorescence from SYBR Green.  Error bars represent standard deviation.  “Control 
Avg” is the average fluorescence from an empty well.  “RFU Threshold” is an approximation of the 














































































18.57 2 18.54 
3 18.50 
Table 4. qRTPCR CT values. 
It can be seen in Figure 4 that the florescence value does not rise when amplifying 
A. nidulans 2161 cDNA for GnTI.  Additionally, fluorescence rises and a CT value is 
returned for A. nidulans 2161 Histone 2B, indicating that cDNA from the strain is 
present, but it does not express f-GnTI nor do the primers amplify any off-target regions.  
Using the equations from 2.2, we find the ratio of mRNA for f-GnTI present in A. 
nidulans 3162 when compared to A. nidulans 3168 to be 
𝑅𝐸 = 2
𝐶𝐸𝑇2−𝐶𝐸𝑇1 = 226.35−22.78 = 11.88 
Similarly, the ratio of Histone 2B mRNA present in A. nidulans 3162 compared to A. 
nidulans 3168 is found by 
𝑅𝐻 = 2
𝐶𝐻𝑇2−𝐶𝐻𝑇1 = 218.57−18.13 = 1.357 
Correcting for the amount of sample loaded to find the relative expression of f-GnTI at 







Therefore, A. nidulans 3162 expresses f-GnTI at the mRNA level 8.754 times more than 
A. nidulans 3168. 
4.3. Western Blot 
 A Western blot was performed to verify expression on f-GnTI at the protein level 
in A. nidulans 3162 and 3168.  Protein was prepared from lysate of A. nidulans 2162, 
3162, and 3168.  The concentration was measured using a BCA assay and run in 
duplicate on an SDS-PAGE gel, loading twice the sample volume in the second lane for 
each sample compared to the first.  Actin was blotted for as a loading control. 
 
Figure 5. Western blot using anti-GnTI primary antibody.  Lane 1) Protein standard, showing a 50 kDa 
band. 2) 8 μg A. nidulans 2161 protein from lysate. 3) 8 μg A. nidulans 3162 protein from lysate. 4) 8 μg A. 
nidulans 3168 protein from lysate. 5) 16 μg A. nidulans 2161 protein from lysate. 6) 16 μg A. nidulans 
3162 protein from lysate. 7) 16 μg A. nidulans 3168 protein from lysate. 
 GnTI is expected to be seen with a molecular weight of 46 kDa.  A band at 46 
kDa can be seen in lane 7, containing 16 μg of protein from A. nidulans 3168 lysate; 
however, this band is not visible in any of the other lanes. 
4.4. Lectin Blot 
 Protein was prepared from cell lysate and run on an SDS-PAGE gel.  
Additionally, spent media from the strains, which should contain secreted protein, was 
also run on the gel.  The gel was then used to prepare a lectin blot using WGA, which has 
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binding specificity for GlcNAc and sialic acid, thus making any proteins with terminally 
GlcNAcylated or sialylated glycans visible. 
 
Figure 6. Lectin blot using WGA.  Lane 1) 6 μg protein from A. nidulans 2161 lysate. 2) 6 μg protein 
from A. nidulans 3162 lysate. 3) 6 μg protein from A. nidulans 3168 lysate. 4) 6 μg protein from A. 
nidulans 2161 spent media. 5) 6 μg protein from A. nidulans 3162 spent media. 6) 6 μg protein from A. 
nidulans 3168 spent media.  A) 40 second camera exposure time.  B) 60 second camera exposure time.  
The red spots are a result of overexposure. 
 The lectin blot shows binding to many proteins from A. nidulans 3162 and 3168 
lysate, but few in A. nidulans 2161 lysate and none in the media of any of the tested 
strains.  To verify the presence of proteins in the media, the samples from the lectin blot 
above were run in an additional SDS-PAGE gel, which was then stained using Coomassie 




Figure 7: Coomassie Blue stain of protein extracts.  Lane 1) Protein standard. 2) 10 μg protein from A. 
nidulans 2161 lysate. 3) 10 μg protein from A. nidulans 3162 lysate. 4) 10 μg protein from A. nidulans 
3168 lysate. 5) 10 μg protein from A. nidulans 2161 spent media. 6) 10 μg protein from A. nidulans 3162 
spent media. 7) 10 μg protein from A. nidulans 3168 spent media. 
 It can be seen in Figure 7 that proteins are present in the samples derived from 
cell lysate, which is consistent with the Western and lectin blots.  While some faint bands 





Chapter 5. Discussion 
5.1. Insertion of GnTIcas 
 Sequencing of PCR products showed the presence of GnTI when using primers 
och1_US_F and och1_DS_R shows the presence of GnTI, however, sequencing using 
och1_US800_F and och1_DS800_R showed the presence of och1, with no alignment for 
GnTI.  This is because och1_US_F and och1_DS_R will anneal to the ends of the 
GnTIcas insert regardless of its location in the genome.  Conversely, och1_US800_F and 
och1_DS800_R are specific for the genomic location of och1 since they anneal to regions 
upstream and downstream of och1, respectively, but not to GnTIcas itself.  Sequencing 
using these primers would return a sequence which aligns with och1 should GnTIcas not 
have been successfully inserted into och1’s location in the genome.  Taken together, 
these results indicate that in A. nidulans 3162 and 3168, GnTIcas has been inserted, 
however not to the target site of the och1 gene.  As a result, the native och1 gene is still 
present in these strains.  Rather than have been targetedly inserted, GnTIcas was 
randomly inserted into the genomes of the transformant strains.  This most likely 
occurred due to the length of the upstream and downstream regions flanking GnTI-dTM.  
Targeted gene insertion is usually accomplished in A. nidulans using at least 800 bp of 
homologous region each upstream and downstream of the insert [19].  Longer lengths of 
homologous regions have been shown to result in higher transformation efficiency in A. 
nidulans.  In this study, only about 400 bp of homologous region was used for each of the 
upstream and downstream regions, which was not enough to result in targeted insertion of 
GnTIcas.  Nonetheless, GnTIcas is present in the genomes of A. nidulans 3162 and 3168. 
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5.2. mRNA Expression of f-GnTI 
 The results of the qRTPCR show that A. nidulans 3162 expresses f-GnTI close to 
nine times more than A. nidulans 3168 at the mRNA level, while A. nidulans 2161 
showed no expression of f-GnTI or any off-target amplicons.  Furthermore, expression of 
histone 2B mRNA is shown in all samples, confirming that cDNA is present and intact in 
all samples.  This indicates that f-GnTI is successfully being expressed in A. nidulans 
3162 and 3168 and is a result of the transformation with GnTIcas.  The difference in f-
GnTI expression levels between the two transformant strains is because the random 
insertion of GnTIcas resulted in the gene integrating into a different location in the 
genome in each of these two strains.  There are many ways in which genomic location 
can affect the expression levels of a gene.  Firstly, due to the way genomic DNA is folded 
in the cell, some locations of the genome are more accessible by transcription machinery 
than others.  The location at which GnTIcas was integrated into A. nidulans 3162 may be 
more readily accessible than where it was integrated into A. nidulans 3168.  Additionally, 
the genomic location may have stronger promoters and/or enhancers in A. nidulans 3162 
than in A. nidulans 3168, which would also result in higher mRNA expression levels. 
5.3. Protein Expression and Activity 
 Protein expression levels were first assessed by Western blot.  The Western blot 
showed multiple bands, indicating that one of the antibodies being used has some non-
specific binding.  Any bands that are the result of non-specific binding should be present 
in all samples, as their expressed proteome is expected to be the same except for the 
presence of f-GnTI.  Amidst these excess bands, there is a band at 46 kDa which appears 
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only in the protein from A. nidulans 3168 lysate.  46 kDa is the expected molecular 
weight for GnTI, implying that f-GnTI is expressed at the protein level the most or only 
in A. nidulans 3168.  Interestingly, this is in contrast to what would be expected based on 
the difference in mRNA expression between the transformant strains as indicated by the 
qRTPCR.  There are many complexities in post-transcriptional modification of mRNA 
and translation, however, so the lack of correlation between mRNA expression levels and 
protein expression is not abnormal. 
 The lectin blot appears significantly darker in lanes loaded with protein from the 
transformant strains’ lysates compared to lanes with protein from A. nidulans 2161 lysate.  
This indicates that there is significantly more terminal GlcNAcs on the glycans of the 
transformant strains compared to the parent strain, signifying that f-GnTI is active in 
these two strains.  All three of the lanes containing protein samples from lysate have a 
blot at the bottom of the membrane.  This could be glycans that were incomplete, as 
GlcNAcs are exposed on fungal N-glycans before the first mannoses are added while the 
glycan is still attached to the dolichol-pyrophosphate on the ER surface (Figure 1).  The 
blot pertaining to A. nidulans 3168 lysate is noticeably darker than that pertaining to A. 
nidulans 3162 lysate, implying that f-GnTI is more active in A. nidulans 3168 than it is in 
A. nidulans 3162.  This is consistent with the results of the Western blot, which show a 
higher protein concentration in A. nidulans 3168.  This also implies that f-GnTI may be 
present on the Western blot in the A. nidulans 3162 samples, but at too low a 
concentration to be seen.  The lectin did not bind to any glycoproteins in the spent media. 
To investigate whether there were any proteins in these samples at all, an 
additional gel was run using the same samples and stained using Coomassie Blue, which 
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would reveal any proteins present.  Coomassie Blue staining did not show a significant 
amount of protein in the spent media, indicating that the lack of lectin binding was a 
result of a lack of protein in the samples.  Since the sample volumes loaded were based 
on protein concentration as determined by a BCA assay, it may be that the media 
composition used induces false positives in this assay.  BCA being a colorimetric assay, it 
is easy to imagine some component of the minimal media absorbs light at a similar 
wavelength as the assay reagents.  To further support this hypothesis, samples containing 
high amounts of protein visibly turn purple during a BCA assay.  Furthermore, one of the 
components of the minimal media used in this experiment, Hutner’s Solution, is a dark 
purple color.  Therefore, it is possible that Hutner’s Solution has a similar absorbance 
wavelength as the BCA reagent and thus interferes with the BCA assay. 
The lane pertaining to A. nidulans 2161 cell lysate in the Coomassie Blue gel is 
noticeably lighter than the lanes pertaining to A. nidulans 3162 and 3168 lysates.  This 
indicates that less protein was loaded into that lane.  While this implies that less protein 
was also loaded into the corresponding lane for the lectin blot, the difference darkness of 
the lanes in the Coomassie Blue gel, and by extension the protein concentration, is not 
enough to account for the vast difference in darkness of the blots on the lectin blot.  
Furthermore, the additional exposure time causes the streaks in lanes 2 and 3 of the lectin 
blot to become significantly darker, whereas lane 1 does not appear to change much.  If 
GlcNAcylated glycans were present in a significant concentration, the extra exposure 
time should have caused the lane to become darker.  Therefore, sample from A. nidulans 
2161 is not simply lighter due to a lower concentration of protein having been added, but 
rather that there is not a significant amount of GlcNAcylated glycans. 
33 
 
The lectin used to produce this lectin blot was WGA, which has binding 
specificity for sialic acid in addition to GlcNAc [27].  While this would raise concerns in 
some systems, fungi are not known to naturally produce sialic acid and no gene 
pertaining to sialic acid was introduced, therefore, it is highly unlikely that the WGA 




Chapter 6. Conclusion 
The primary aim of this study was to produce an Aspergillus nidulans strain 
which could produce an N-glycan containing one GlcNAc, which could then serve as a 
foundation for further humanization of the glycosylation pathway.  While GnTIcas was 
not successfully targetedly inserted into och1’s location in the genome, the resulting 
random insertion still provided sufficient expression of f-GnTI to cause a change in the 
transformant strains’ glycans, presumably being the addition of terminal GlcNAcs.  
Continuing forward, it may be necessary to delete och1 to further reduce unwanted 
mannosylation of N-glycans. 
Furthermore, the success of the och1-GnTI fusion protein in affecting 
glycosylation is indicative of a simpler method for glycoengineering going forward.  
Research groups have formerly used combinatorial libraries for similar studies, which 
involves creating libraries of random fusions between several gene and signal peptide 
combinations and high throughput transformant screening.  Comparatively, this strategy 
of selecting signal peptides and transmembrane domains from fungal glycosylation genes 
to fuse with mammalian glycosylation genes is relatively simple and may continue to be 




Chapter 7. Future Work 
This study has been the beginning of a long process which is required to fully 
humanize the fungal glycan.  As we were unable to perform any structural studies of the 
N-glycans resulting from this work, it would be useful to perform such studies to 
elucidate the specific manner in which the insertion of f-GnTI affected the glycosylation.  
Following this work, och1 can be deleted to reduce mannosylation of N-glycans, as well 
as other fungal mannosyltransferases such as mnn9 and van1 which function in the fungal 
Golgi apparatus.  Additionally, GnTII needs to be inserted into the strain.  Not only 
would this function to add GlcNAc to the α-1,6 mannose branch of the glycans, but it 
could also serve to reduce mannosylation of glycans by way of competing for substrate 
with mannosyltransferases, as has been seen in the yeast Pichia pastoris [29].  After the 
addition of GnTII, galactosyltion and sialylation of the N-glycans need to be achieved.  
Once sialylation of glycans has been achieved in A. nidulans, a functional therapeutic 
glycoprotein product could then be introduced and tested for efficacy. 
Aspergillus nidulans serves as a model organism for filamentous fungi due to the 
fact that it is relatively easy to work with and well understood; however, Aspergillus 
niger is known to secrete higher amounts of protein, and therefore is more industrially 
relevant.  Once the methodologies for humanizing the glycan in A. nidulans have been 
determined, it would still be more beneficial from an industrial perspective to transfer the 
genetic technology to A. niger.  After humanization of glycosylation in fungi has been 
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• Registered samples in company database using FDA and CE protocol sample 
naming guidelines and resolved sample name discrepancies. 
• Assisted in writing of FDA protocol. 
• Trained colleagues on lab protocols. 





Lab Assistant – Moores Cancer Center, UCSD, Reid Lab (July 2014 – June 2015) 
• Maintained HEK 293 cell lines used in development of viral vectors for the 
purpose of melanoma treatment. 
• Routinely measured mouse tumors to monitor tumor growth. 
• Purified viral DNA. 
• Monitored laboratory glassware and consumables and autoclaved equipment as 
needed. 
• Inventoried supply stocks. 
Laboratory Skills 
• Transgenic expression in filamentous 
fungi 
• Western blot 
• Fusion PCR • Lectin blot 
• qPCR • His-tag affinity protein purification 
• RTPCR • MALDI-TOF mass spectrometry 
• DNA and RNA purification • Selection marker recycling 
• Mouse handling • Filamentous fungal, yeast, adherent 
mammalian, and bacterial cell cultures 
Software Skills 
• Microsoft Word, PowerPoint, Excel • Adobe Illustrator 
• NCBI BLAST • Maple 
Publications 
• Chung, C. Y., Majewska, N. I., Wang, Q., Paul, J. T., & Betenbaugh, M. J. 
(2017). SnapShot: N-glycosylation processing pathways across 
kingdoms. Cell, 171(1), 258-258. 
 
